Form 425 Cyclo Therapeutics, Inc. Filed by: Cyclo Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq drags on Wall St as AI slowdown fears hammer Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
August 26, 2024 5:03 AM EDTAscendiant Capital analyst Lucas Ward lowered the price target on Cyclo Therapeutics (NASDAQ: CYTH) to $0.95 (from $2.60) while maintaining a Buy rating.
The analyst comments "Company completes enrollment in phase 3 trial, affirms regulatory timeline: On May 30, the company announced it has completed enrollment for its... More
